Clinical trials: X-linked Retinoschisis
Retinitis Pigmentosa, Stargardt Macular Dystrophy
Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.
- Conditions
- Retinitis Pigmentosa, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy From Age-related Macular Degeneration
- Trial name
- DEFINE-IRD (NCT07502664)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Ray Therapeutics, Inc.
Retinoschisis, X-Linked
Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis
Background: X-linked juvenile retinoschisis (XLRS) is caused by changes in the RS1 gene. These changes cause abnormal function of the eye protein retinoschisin.
- Trial name
- NCT02317887
- Testing
- RS1 AAV Vector
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- VegaVect, Inc.
X-linked Retinoschisis
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
This study will evaluate the safety and efficacy of ATSN-201 in subjects ≥ 5 years of age with RS1-associated X-linked retinoschisis (XLRS).
- Trial name
- LIGHTHOUSE (NCT05878860)
- Testing
- ATSN-201
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 97 people
- Sponsor
- Atsena Therapeutics Inc.
Retinitis Pigmentosa, Choroideremia
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.
- Conditions
- Retinitis Pigmentosa, Choroideremia, Stargardt Macular Dystrophy, Stargardt Disease
- Trial name
- NCT06375239
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Ray Therapeutics, Inc.
X-linked Retinoschisis
Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis.
- Trial name
- NCT02416622
- Testing
- rAAV2tYF-CB-hRS1
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Beacon Therapeutics
X-linked Retinoschisis
Safety and Efficacy Study of Novel Gene Therapy ZM-01 for X-linked Retinoschisis Patients
This trial is meant to evaluate the safety and efficacy of ZM-01 of X-linked retinoschisis. Unilateral intravitreal injections (IVT) will be given into the subject's Study Eye.
- Trial name
- NCT06066008
- Testing
- ZM-01-L, ZM-01-H
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Zhongmou Therapeutics
Retinoschisis, Retinal Disease
Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis
The goal of this clinical trial is to evaluate the safety and efficacy of IVB102 injection in subjects with XLRS.
- Conditions
- Retinoschisis, Retinal Disease, Retinal Degeneration, Eye Diseases
- Trial name
- NCT06289452
- Testing
- IVB102 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- InnoVec Biotherapeutics Inc.
X-linked Retinoschisis, XLRS
Clinical Evaluation of Patients With X-linked Retinoschisis
The purpose of this study is to evaluate subjects with X-linked retinoschisis in a clinical setting to collect data on disease progression.
- Trial name
- NCT02331173
- Testing
- Dorzolamide 2% TID or brinzolamide 1% TID
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- Beacon Therapeutics